Ferring Pharmaceuticals has agreed to acquire Gameto, a cell engineering company focused on womens reproductive health, in a transaction worth up to 1.3825 billion dollars. The companies signed the agreement on October 27, 2026. The headline figure includes development, regulatory and commercial milestone payments, and neither company disclosed the upfront payment or an expected closing date. Completion remains subject to closing conditions, and the two companies will operate independently until the deal closes.
The prize is Fertilo, Gametos lead programme, which uses ovarian support cells derived from induced pluripotent stem cells to mature eggs outside the body. The approach is designed to move much of the hormone stimulation burden of a standard IVF cycle into the laboratory, and Gameto says it could shorten a fertility treatment cycle to as little as three days. Fertilo is cleared for use in Australia and parts of Latin America and is in a Phase 3 trial in the United States, the FIRST study, with pregnancy rate at 12 weeks as the primary efficacy endpoint.
The announcement is explicit that Gametos in vitro maturation programme is investigational in the United States and has not been approved by the Food and Drug Administration. No new efficacy or safety results were released with the deal. Gameto, founded in 2020 and based in Austin, Texas, has raised 127 million dollars since founding, according to trade reporting of the announcement.
For Ferring, a privately owned company headquartered in Saint Prex, Switzerland, the deal extends an existing reproductive medicine franchise built on hormone products used in IVF, including Menopur and Rekovelle. The structure tells the risk story plainly: a fertility leader is willing to commit more than a billion dollars of potential value to laboratory egg maturation, but it has written the contract so that most of that value is paid only if the Phase 3 trial and regulators deliver.